Cartesian Therapeutics Inc

In Stage 2 advancing, medium-term bullish structure remains intact with higher highs and rising EMAs, but terminal blow-off top and exhaustion patterns combined with overbought readings call for caution. Price is extended and requires a pullback into the rising EMAs or prior breakout zone for a favorable entry. Long-term downtrend persists as a structural headwind.

• ↑Strong momentum factor indicates renewed investor traction.
• ↑Zacks upgraded to hold with $32.60 average target.
• ↓Deep negative earnings yield and weak profitability factors signal cash burn.